Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects (NSERC partnered)

McGill University

$371,615.00

Acceleration and Intensification of Cell Culture-Produced Influenza Vaccines for Rapid Response to Pandemic Situation

FY 2016-17

Summary
Over the last decades, significant investments have been directed by the US Department of Health and other national and international authorities to build capacities and implement preparedness plans to face influenza pandemic situations. During influenza pandemic, countries have increased vaccine demand for their own population and it is critical to have rapid availability of matched vaccines. However, it may be highly problematic to meet the expected vaccine demand with current egg-based manufacturing process, for instance in the case of an avian pandemic strain that could potentially disrupt the supply chain of eggs. Therefore, alternative production processes, including cell culture and plant-based production platforms using recombinant technology, have been developed and validated following recommendations from National and International Health authorities to develop alternative and complementary technologies for rapid and effective responses in emergency situations. Currently in Canada, influenza vaccine production is carried out by only one manufacturer using egg-based production technology. Although plant-based process and production capacities are currently being developed by Medicago, for a solid and sustain preparedness plan to face influenza potential pandemics and other emerging infectious disease, it is highly strategic for Canada to invest in cell culture produced viral vaccine capacities as it is the case in the US. Taking advantages of advanced technologies recently developed in the applicant's laboratories and cell-culture production capacities already operational at Pnuvax Inc., we aim to accelerate and intensify, by addressing the limitations at all process steps, the development and validation of a cell-culture production platform for pandemic influenza vaccines as a national alternative and complementary vaccines source.
Program
Collaborative Health Research Projects (NSERC partnered)
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
361102
Name
Kamen Amine
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
Acceleration and Intensification of Cell Culture-Produced Influenza Vaccines for Rapid Response to Pandemic Situation
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$371,615
Cihrequipment2
$0
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Bioprocess Development; Cell Culture Engineering; Cell/Virus Interaction; Immunogenicity Studies In Animals; Influenza Virus; Pandemic Situation; Potency Assays; Process Analytical Tecchnology; Vaccine; Vaccine Manufacturing
Abstract
Over the last decades, significant investments have been directed by the US Department of Health and other national and international authorities to build capacities and implement preparedness plans to face influenza pandemic situations. During influenza pandemic, countries have increased vaccine demand for their own population and it is critical to have rapid availability of matched vaccines. However, it may be highly problematic to meet the expected vaccine demand with current egg-based manufacturing process, for instance in the case of an avian pandemic strain that could potentially disrupt the supply chain of eggs. Therefore, alternative production processes, including cell culture and plant-based production platforms using recombinant technology, have been developed and validated following recommendations from National and International Health authorities to develop alternative and complementary technologies for rapid and effective responses in emergency situations. Currently in Canada, influenza vaccine production is carried out by only one manufacturer using egg-based production technology. Although plant-based process and production capacities are currently being developed by Medicago, for a solid and sustain preparedness plan to face influenza potential pandemics and other emerging infectious disease, it is highly strategic for Canada to invest in cell culture produced viral vaccine capacities as it is the case in the US. Taking advantages of advanced technologies recently developed in the applicant's laboratories and cell-culture production capacities already operational at Pnuvax Inc., we aim to accelerate and intensify, by addressing the limitations at all process steps, the development and validation of a cell-culture production platform for pandemic influenza vaccines as a national alternative and complementary vaccines source.
Competitiondate
201610
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kamen, Amine; Li, Xuguang
Approvedterm
3 ans 0 mois
Cihrcontribution2
Major Initiatives #2~ $371,615~ $0~